New drug cocktail aims to shrink oral tumors before surgery
NCT ID NCT07484139
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery to people with a type of oral cancer that is HPV-negative and can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before the operation. About 26 participants will be enrolled, and the study will check how many have a major or complete response in their tumor tissue after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XL-092 (Zanzalintinib) and pembrolizumab (Keytruda)
What this could lead to
If this works, it could lead to a new treatment option that shrinks oral cavity tumors before surgery, potentially improving survival and reducing recurrence.
What could go wrong
This is a small, early-phase trial with only 26 participants. The combination may cause side effects, and it's not yet known if it works better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Contact
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••